Phase II trial of bevacizumab and fotemustine in recurrent grade III gliomas.
Riccardo Soffietti
No relevant relationships to disclose
Elisa Trevisan
No relevant relationships to disclose
Chiara Bosa
No relevant relationships to disclose
Luca Bertero
No relevant relationships to disclose
Roberta Ruda
No relevant relationships to disclose